Research advance in mesenchymal stem cell-based therapy for diabetic nephropathy.

IF 2.5 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Archives of Physiology and Biochemistry Pub Date : 2025-06-01 Epub Date: 2024-12-30 DOI:10.1080/13813455.2024.2447532

Yan Hui, Yuyang Dong, Yi Liu

引用次数: 0

Abstract

Diabetic nephropathy (DN) is the main cause of end-stage kidney disease and has become a global public health problem. Currently, treatment of DN is limited to alleviating disease progression rather than curing diseases or restoring renal function, thus more effective therapeutic strategies against DN are urgently needed. Mesenchymal stem cells (MSCs) have been widely applied in the prevention and treatment of DN. Preclinical studies have proved that MSCs exhibited favourable therapeutic effects on DN by regulation of hyperglycaemia, reduction of urinary albumin, and protecting renal function. Hence this review provides an overview of the biological properties of MSCs, summarises the regulatory mechanisms of MSC-based therapy for DN, presents ongoing or completed clinical trials, as well as discusses the potential challenges and new strategies of MSCs in the treatment of DN, with the aim of providing a balanced and unbiased view of MSC transplantation as promising therapeutic strategies for DN.

查看原文本刊更多论文

间充质干细胞治疗糖尿病肾病的研究进展。

糖尿病肾病（DN）是终末期肾脏疾病的主要病因，已成为一个全球性的公共卫生问题。目前，对DN的治疗仅限于缓解疾病进展，而不是治愈疾病或恢复肾功能，因此迫切需要更有效的治疗DN的策略。间充质干细胞（Mesenchymal stem cells, MSCs）已广泛应用于DN的防治。临床前研究证明，MSCs通过调节高血糖、降低尿白蛋白和保护肾功能，对DN具有良好的治疗作用。因此，本文综述了间充质干细胞的生物学特性，总结了以间充质干细胞为基础的DN治疗的调控机制，介绍了正在进行或已完成的临床试验，并讨论了间充质干细胞在DN治疗中的潜在挑战和新策略，旨在为间充质干细胞移植作为DN的治疗策略提供一个平衡和公正的观点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Archives of Physiology and Biochemistry ENDOCRINOLOGY & METABOLISM-PHYSIOLOGY

CiteScore

6.90

自引率

3.30%

发文量

期刊介绍： Archives of Physiology and Biochemistry: The Journal of Metabolic Diseases is an international peer-reviewed journal which has been relaunched to meet the increasing demand for integrated publication on molecular, biochemical and cellular aspects of metabolic diseases, as well as clinical and therapeutic strategies for their treatment. It publishes full-length original articles, rapid papers, reviews and mini-reviews on selected topics. It is the overall goal of the journal to disseminate novel approaches to an improved understanding of major metabolic disorders. The scope encompasses all topics related to the molecular and cellular pathophysiology of metabolic diseases like obesity, type 2 diabetes and the metabolic syndrome, and their associated complications. Clinical studies are considered as an integral part of the Journal and should be related to one of the following topics: -Dysregulation of hormone receptors and signal transduction -Contribution of gene variants and gene regulatory processes -Impairment of intermediary metabolism at the cellular level -Secretion and metabolism of peptides and other factors that mediate cellular crosstalk -Therapeutic strategies for managing metabolic diseases Special issues dedicated to topics in the field will be published regularly.